Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis. [electronic resource]
Producer: 20130705Description: E1007-11 p. digitalISSN:- 1945-7197
- Aged
- Aged, 80 and over
- Bone Density -- drug effects
- Bone Density Conservation Agents -- therapeutic use
- Calcium, Dietary -- therapeutic use
- Cholecalciferol -- therapeutic use
- Combined Modality Therapy
- Dietary Supplements
- Diphosphonates -- therapeutic use
- Female
- Gene Expression Regulation -- drug effects
- Humans
- Ibandronic Acid
- Leukocytes, Mononuclear -- drug effects
- Middle Aged
- Organometallic Compounds -- therapeutic use
- Osteoporosis, Postmenopausal -- blood
- Osteoprotegerin -- blood
- RANK Ligand -- blood
- RNA, Messenger -- metabolism
- Receptor Activator of Nuclear Factor-kappa B -- blood
- Thiophenes -- therapeutic use
No physical items for this record
Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.